2025-12-24 - Analysis Report
Okay, here's a comprehensive analysis of UnitedHealth Group (UNH) based on the provided data, covering all requested points.

**1) Return Rate Comparison**

*   **Ticker:** UNH (UnitedHealth Group Inc) - A diversified health care company.
*   **UNH Cumulative Return:** -18.396%
*   **VOO (S&P 500) Cumulative Return:** 100.884%
*   **Divergence:**
    *   Current: -119.3
    *   Relative Divergence: 6.8 (meaning the current divergence is near the bottom of its historical range)

**Analysis:**  UNH has significantly underperformed the S&P 500 (VOO) during the analyzed period.  The negative cumulative return compared to the S&P 500's substantial positive return highlights a considerable performance gap. The low relative divergence suggests that the underperformance is near its worst level in the historical range considered.

**Alpha, Beta, and Financial Data Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 58.0%   | 66.4%   | 30.0%   | 0.1    | 198.1  |
| 2016-2018  | 41.0%   | 70.4%   | 26.0%   | 0.1    | 223.9  |
| 2017-2019  | 36.0%   | 73.8%   | 14.0%   | 0.2    | 264.2  |
| 2018-2020  | -43.0%  | 81.2%   | -67.0%  | 0.5    | 315.1  |
| 2019-2021  | 16.0%   | 81.2%   | -30.0%  | 1.5    | 451.2  |
| 2020-2022  | -1.0%   | 81.2%   | 0.0%    | 1.5    | 476.4  |
| 2021-2023  | 24.0%   | 80.8%   | 23.0%   | 0.4    | 473.1  |
| 2022-2024  | -27.0%  | 78.8%   | -47.0%  | 0.3    | 454.6  |
| 2023-2025  | -61.0%  | 79.8%   | -126.0% | 1.2    | 294.2  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR has declined significantly in recent periods, moving from strong growth in earlier years to negative growth in the last few periods. This is a major red flag.
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating substantial risk and volatility in UNH's returns.
*   **Alpha:** Alpha has turned negative and severely so in recent years.  This means UNH is significantly underperforming relative to its risk-adjusted expected return. The recent Alpha of -126% is extremely concerning.
*   **Beta:** Beta has fluctuated, increasing notably in some periods (1.5) before decreasing, indicating varying sensitivity to market movements. A beta near or above 1 suggests higher volatility than the market.
*   **Cap(B) (Market Capitalization in Billions):**  Market capitalization generally increased over the historical period, but shows a drop recently, correlating with the negative performance.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 327.42
*   **Last Market Data:**
    *   Price: 324.8
    *   Previous Close: 325.16
    *   Change: -0.11
*   **5-day SMA:** 332.498
*   **20-day SMA:** 329.988
*   **60-day SMA:** 340.1082

**Analysis:**  The current price is below both the 5-day and 20-day SMAs, indicating a short-term downward trend.  The 5-day SMA is also below the 20-day SMA, further confirming this trend.  The 60-day SMA is significantly higher than the current price, suggesting a longer-term downtrend as well.

**3) Indicator Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 52.25 (Neutral)
*   **PPO (Percentage Price Oscillator):** 0.1151 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08)
*   **Recent (20 days) relative divergence change:** -2.3 (단기하락 - Short-term decline)
*   **Last Price Change:** {'price': 324.8, 'previousClose': 325.16, 'change': -0.11} (Indicates a small recent decline)
*   **Expected Return (%):** -283.7% (Extremely Negative)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is near 50, indicating a neutral condition, with neither overbought nor oversold conditions.
*   The PPO value suggests short-term price movements are closely tracking longer-term trends.
*   The Hybrid Signal suggests a strategy of buying a substantial portion of the holding with available cash, but this is tempered by the relatively safe (MRI) rating and the dividend yield.
*   The negative change in relative divergence confirms a recent underperformance compared to the S&P 500.
*   **The extremely negative expected return is a major cause for concern.** It suggests very poor future performance based on the current analysis.

**4) Recent News & Significant Events**

*   **Audits, Washington Policy Pressure, and Analyst Price Targets:** This suggests regulatory scrutiny and uncertainty regarding future policy impacts.
*   **Audit Reforms and Regulatory Scrutiny:** Reinforces the concern about potential regulatory headwinds.
*   **UnitedHealth is expanding OptumRX:**  OptumRX expansion is generally a positive development, potentially indicating growth and market share gains, but requires further investigation to determine whether it will address the underlying issues.
*   **Prediction: UnitedHealth Group Stock Will Soar in 2026:** This is an optimistic outlook, but needs to be considered in light of the other negative news and data.
*   **How UnitedHealth Became the Worst Dow Stock of 2025:** This headline confirms the poor recent performance highlighted by the return rate data.
*   **Yousif Capital Management LLC Lowers Stock Holdings:**  Institutional selling pressure adds to the negative sentiment.

**Analysis:**  The news flow is mixed, with some positive developments (OptumRX expansion) but significantly overshadowed by negative news regarding regulatory pressure, poor performance, and institutional selling.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.96)
*   **Target Price:** 392.24 (average)

**Analysis:** The analyst consensus remains positive, with a "Buy" rating and a target price significantly above the current price.  This suggests analysts believe the stock is undervalued and has potential for recovery, but should be considered with the all of the other data.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출          |
|------------|-------|---------------|
| 2025-10-28 | 2.59  | 113.16 B$     |
| 2025-08-11 | 3.76  | 111.62 B$     |
| 2025-05-07 | 6.9   | 109.58 B$     |
| 2024-11-04 | 6.56  | 100.82 B$     |
| 2025-10-28 | 6.56  | 100.82 B$     |

**Analysis:**  While revenue has been generally increasing, EPS has been volatile and shows a recent drop. This suggests that while the company is growing its top line, profitability is being squeezed. Duplicated records might indicate data inconsistency.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $113.16B  | 18.24%        |
| 2025-06-30   | $111.62B  | 17.93%        |
| 2025-03-31   | $109.58B  | 21.70%        |
| 2024-12-31   | $100.81B  | 21.14%        |
| 2024-09-30   | $100.82B  | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | $95.79B   | 2.45% |
| 2025-06-30   | $94.72B   | 3.60% |
| 2025-03-31   | $95.04B   | 6.62% |
| 2024-12-31   | $92.66B   | 5.98% |
| 2024-09-30   | $94.53B   | 6.41% |

**Analysis:**

*   **Revenue:** Revenue has been consistently growing.
*   **Profit Margin:**  Profit margins have decreased in recent quarters, consistent with the EPS analysis.
*   **Equity:** Equity has shown modest growth.
*   **ROE (Return on Equity):** ROE has declined significantly in recent quarters, indicating a decrease in profitability relative to shareholder equity.

**7) Comprehensive Analysis (Summary)**

Overall, the analysis paints a concerning picture for UNH.

*   **Poor Performance:** UNH has significantly underperformed the S&P 500, with a negative cumulative return and a low relative divergence.
*   **Declining Growth and Profitability:**  CAGR, Alpha, EPS, profit margins, and ROE have all declined significantly in recent periods.
*   **Regulatory Risks:** News headlines highlight regulatory scrutiny and potential policy headwinds.
*   **Mixed Signals:** While analyst consensus remains positive, institutional selling and negative news outweigh the optimism.
*   **Technical Indicators:** Technical indicators suggest a short-term and potentially longer-term downtrend.
*   **Extremely Negative Expected Return:** The expected return is extremely negative, indicating a high probability of continued underperformance.

**Conclusion:**

Based on the provided data, investing in UNH at this time appears to be very risky. While analysts maintain a "Buy" rating, the negative trends in performance, profitability, and regulatory environment raise significant concerns. The extremely negative expected return suggests that the risks outweigh the potential rewards. Further research and due diligence are crucial before considering an investment in UNH. The OptumRX expansion should be examined closely to determine its potential to offset the negative trends.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.